Saturday 17 October 2026 Export ATNM’s income statement to Excel — free account

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $90,000.00, up 11.1% from fiscal 2023. In the quarter to June 2026, revenue grew 77,677.8%, EPS grew 504.6% and free cash flow fell 4.91%, each against the same quarter a year earlier.

1.13 0.07 +6.60%

Follow ATNM

Alert me

Market cap: $33.3M
P/E: 3.1×
Fwd P/E: −1.3×
Dividend yield: —
F-score: n/a
Altman Z: −11.85
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 1.62%

Capital & Financial Ratios $m

Market Cap 33.32

Revenue 35.14

Net Income 11.31

Free Cash Flow (23.25)

Net Debt (36.47)

Current Ratio 4.08

Debt/Equity 0.00

P/E ratio 3.14

Fwd P/E (1.29)

P/S ratio 1.01

P/B ratio 1.17

Past 5Y EPS Growth —

This Y EPS Growth 116.21%

Next Y EPS Growth (420.75%)

Next Y revenue growth 19,344.44%

Next 5Y EPS Growth 20.23%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 4.82%

10-year low 10-year high

P/B against its own 10 years 4.50%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	77	73	48	36
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	78	75	49	38

	2023	2024	2025	Q'26
Payables	8	8	7	9
ST’ Debt	—	—	—	—
Other	—	—	—	—
	8	8	8	9

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(57.15%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(9.80%)	(33.74%)	(50.97%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	35	—	—	—
’25	—	—	0	—	0
’23	—	—	—	—	0
’22	1	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(5)	—	—	—
’25	(8)	(5)	(6)	(5)	(25)
’24	(7)	(8)	(12)	(6)	(33)
’23	(15)	(14)	(11)	(7)	(47)
’22	(6)	28	(6)	(8)	9
’21	(6)	(5)	(6)	(5)	(21)
’20	(6)	(5)	(5)	(6)	(22)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(6)	—	—	—
’25	(8)	(5)	(6)	(5)	(25)
’24	(7)	(8)	(12)	(6)	(33)
’23	(15)	(14)	(11)	(7)	(47)
’22	(6)	28	(6)	(8)	8
’21	(6)	(5)	(6)	(5)	(21)
’20	(6)	(5)	(5)	(7)	(22)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.18)	0.89	—	—	—
’25	(0.51)	(0.22)	(0.16)	(0.19)	(1.09)
’24	(0.31)	(0.38)	(0.37)	(0.21)	(1.27)
’23	(0.43)	(0.58)	(0.49)	(0.33)	(1.83)
’22	(0.23)	(0.33)	(0.38)	(0.42)	(1.37)
’21	(0.29)	(0.25)	(0.30)	(0.37)	(1.20)
’20	(0.98)	(0.41)	(0.36)	(0.09)	(1.83)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	25.80	16.17	9.96	5.70	4.71	5.70	4.41	4.00	1.10	1.03	Analyst estimates 2026–2028 Powerpack
	High	105.00	51.60	25.95	21.27	19.47	10.30	15.12	14.70	10.24	2.41
People
People	Employees	23	25	30	25	32	32	49	49	37	25
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.04	0.02	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	1	1	0	—	0
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	100.00	100.00	100.00	—	100.00
	EBT	(24)	(27)	(24)	(22)	(22)	(25)	(33)	(49)	(38)	(34)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	(2,165.56)	(3,205.53)	(60,269.14)	0.00	(37,652.22)
	Net income	(24)	(27)	(24)	(22)	(22)	(25)	(33)	(49)	(38)	(34)
	Depreciation	0	0	0	0	0	1	1	1	1	1
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.06	0.04	0.00	0.00	0.00
	Earnings	(15.01)	(12.01)	(6.61)	(4.33)	(1.83)	(1.17)	(1.37)	(1.83)	(1.27)	(1.09)
	Cash flow	(12.88)	(9.70)	(5.83)	(4.31)	(1.78)	(1.01)	0.36	(1.78)	(1.10)	(0.79)
	Capex	(0.04)	(0.01)	(0.03)	(0.01)	(0.02)	(0.01)	(0.02)	(0.01)	0.00	0.00
	Free cash flow	(12.92)	(9.71)	(5.85)	(4.33)	(1.80)	(1.02)	0.34	(1.78)	(1.10)	(0.79)
	Book value	11.16	6.15	2.50	1.13	5.05	3.58	2.75	1.37	1.09	0.25
	Shares, m	2	2	4	5	12	21	24	27	30	31
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	—	0.00
	P/S	—	—	—	—	—	108.06	234.86	137.41	—	235.70
	P/B	—	—	—	—	—	1.68	3.64	3.89	—	5.42
	EV/Sales	—	—	—	—	—	39.64	130.76	62.99	—	(30.94)
	EV/FCF	—	—	—	—	—	(2.16)	16.27	(1.37)	—	0.23
Cash, $m
Cash, $m	Operating cash flow	(21)	(22)	(21)	(21)	(22)	(21)	9	(47)	(33)	(25)
	Capex	0	0	0	0	0	0	0	0	0	0
	Free cash flow	(21)	(22)	(21)	(22)	(22)	(21)	8	(47)	(33)	(25)
Balance, $m
Balance, $m	Working capital	18	13	8	5	60	73	100	70	66	41
	Total debt	—	—	0	0	0	0	2	0	0	—
	Net debt	(21)	(17)	(14)	(9)	(64)	(78)	(107)	(77)	(73)	(48)
	Shareholders’ equity	18	14	9	6	61	74	66	36	33	8
Returns, %
Returns, %	ROA	(99.04)	(130.19)	(142.38)	(164.92)	(56.92)	(33.76)	(33.94)	(49.91)	(48.30)	(52.67)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(121.66)	(167.94)	(210.41)	(302.99)	(66.35)	(36.74)	(47.16)	(94.92)	(110.63)	(166.96)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LIANY LianBio Sponsored ADR	$34.2M	0.0×	—	—	n/m	+1,107.59% (above 0%: growing)	0.00%	0.00%	Compare
CRVO CervoMed Inc.	$34.0M	— (loss-making)	— (loss-making)	−99.60% (below 0%: shrinking)	n/m	−6.20% (below 0%: shrinking)	100.00%	0.00%	Compare
IRLA Quince Therapeutics, Inc.	$33.8M	— (loss-making)	—	—	n/m	−63.65% (below 0%: shrinking)	0.00%	0.00%	Compare
ALGS Aligos Therapeutics, Inc.	$33.7M	— (loss-making)	— (loss-making)	+2,778.55% (above 0%: growing)	n/m	−59.81% (below 0%: shrinking)	100.00%	(6.80%)	Compare
ATNM Actinium Pharmaceuticals, Inc.	$33.3M	3.1×	— (loss-making)	+77,677.78% (above 0%: growing)	n/m	−4.91% (below 0%: shrinking)	100.00%	78.76%
BCTX BRIACELL THERAP	$32.8M	1.5×	—	—	n/m	+0.21% (above 0%: growing)	0.00%	0.00%	Compare
GNTA Genenta Science S.p.A. Unsponsored ADR	$32.3M	—	—	—	—	+35.94% (above 0%: growing)	0.00%	—	Compare
MGX Metagenomi Therapeutics, Inc.	$31.9M	— (loss-making)	— (loss-making)	−103.02% (below 0%: shrinking)	n/m	+7.98% (above 0%: growing)	100.00%	11,195.72%	Compare
GRDX GridAI Technologies Corp.	$31.8M	— (loss-making)	—	—	n/m	−2,640.98% (below 0%: shrinking)	(42.49%)	(15,258.21%)	Compare
Median of peers	$33.2M	—	—	−99.60%	—	−2.99%	0.00%	0.00%

All 614 Biotechnology stocks →

Actinium Pharmaceuticals, Inc. (ATNM) key facts

Concern: Actinium Pharmaceuticals, Inc. reported a net loss of $33.9 million, or a loss of $1.09 per share, for fiscal 2025.
Strength: Actinium Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $90,000.00, up 11.1% from fiscal 2023.
Actinium Pharmaceuticals, Inc. (ATNM) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, ATNM traded at $1.13, a market capitalization of $33.3 million.
At that price the stock trades at 3.1× trailing-twelve-month earnings and 1.0× sales.
Return on equity was −167.0% and debt-to-equity 0.00.
Its Altman Z-score is −11.85 (distress zone) for fiscal 2025.